$CNNA Cann American Corp. Provides Update on Prodigy Stem Cell Acquisition and Company Direction
https://www.accesswire.com/745892/Cann-Americ...-Direction
RUTHERFORD, NJ / ACCESSWIRE / March 27, 2023 / Cann American Corp. (OTC PINK:CNNA), the "Company", a holding company building a diverse portfolio of intellectual properties, is pleased to announce a shareholder update for 2023.
On March 1, 2023, the Company completed the acquisition of Prodigy Stem Cell. With this acquisition the Company intends to expand its overall direction as a holding company engaged in alternative therapeutics ranging from CBD to regenerative medicines.
The Company will be, in the near term, focused primarily on expanding the Prodigy brand and vision originally launched under Prodigy's founder and recently appointed CNNA director, Pete Caruso.
Based on publicly available research reports, the global stem cell market is currently valued at approximately $12 billion with projections to reach approximately $30 billion by 2030. Prodigy expects its business model to capture significant US market share over the next several years. With exclusive laboratory access to the highest quality stem cells in the market, Prodigy is initiating a multi-prong business plan.
As a wholesaler Prodigy will be offering its product lines to Dr.'s, sports medicine facilities, plastic surgery centers, and similar health and wellness clinics nationwide. This will be achieved through an extensive marketing campaign including conventions and brand ambassadorships. Prodigy has already began to recruit high profile athletes, who are also current clients, to promote the Prodigy brand.
Secondly, Prodigy intends to rapidly expand into several of its own Prodigy branded wellness centers at strategic locations throughout the US. The Company is currently planning to launch a new facility in Florida, in addition to its flagship New Jersey office, within the coming weeks. Prodigy locations will be strategically opened in regions that host major sporting facilities and professional athletic training camps as its target market.
As the Company aggressively embarks on advancing Prodigy Stem Cell, it is also nearing conclusion of its financial audits to up-list from alternative reporting to SEC reporting. With the belief that Prodigy is a world class product, the Company is committed to representing its portfolio on at least the OTCQB tier as soon as possible.
Stated Cann American CEO, Jason Tucker: "I'm extremely pleased to be appointed as CEO with Prodigy acting as our flagship asset. My previous experience with successful SEC audits has put me in the unique position to take CNNA into its next chapter. In addition to bringing on Mr. Caruso as a director, we will be announcing additional appointments soon and we will keep investors updated on our progress going forward."
https://www.accesswire.com/745892/Cann-Americ...-Direction
RUTHERFORD, NJ / ACCESSWIRE / March 27, 2023 / Cann American Corp. (OTC PINK:CNNA), the "Company", a holding company building a diverse portfolio of intellectual properties, is pleased to announce a shareholder update for 2023.
On March 1, 2023, the Company completed the acquisition of Prodigy Stem Cell. With this acquisition the Company intends to expand its overall direction as a holding company engaged in alternative therapeutics ranging from CBD to regenerative medicines.
The Company will be, in the near term, focused primarily on expanding the Prodigy brand and vision originally launched under Prodigy's founder and recently appointed CNNA director, Pete Caruso.
Based on publicly available research reports, the global stem cell market is currently valued at approximately $12 billion with projections to reach approximately $30 billion by 2030. Prodigy expects its business model to capture significant US market share over the next several years. With exclusive laboratory access to the highest quality stem cells in the market, Prodigy is initiating a multi-prong business plan.
As a wholesaler Prodigy will be offering its product lines to Dr.'s, sports medicine facilities, plastic surgery centers, and similar health and wellness clinics nationwide. This will be achieved through an extensive marketing campaign including conventions and brand ambassadorships. Prodigy has already began to recruit high profile athletes, who are also current clients, to promote the Prodigy brand.
Secondly, Prodigy intends to rapidly expand into several of its own Prodigy branded wellness centers at strategic locations throughout the US. The Company is currently planning to launch a new facility in Florida, in addition to its flagship New Jersey office, within the coming weeks. Prodigy locations will be strategically opened in regions that host major sporting facilities and professional athletic training camps as its target market.
As the Company aggressively embarks on advancing Prodigy Stem Cell, it is also nearing conclusion of its financial audits to up-list from alternative reporting to SEC reporting. With the belief that Prodigy is a world class product, the Company is committed to representing its portfolio on at least the OTCQB tier as soon as possible.
Stated Cann American CEO, Jason Tucker: "I'm extremely pleased to be appointed as CEO with Prodigy acting as our flagship asset. My previous experience with successful SEC audits has put me in the unique position to take CNNA into its next chapter. In addition to bringing on Mr. Caruso as a director, we will be announcing additional appointments soon and we will keep investors updated on our progress going forward."
